Literature DB >> 3306508

Recurrent anaphylaxis in menstruating women: treatment with a luteinizing hormone-releasing hormone agonist--a preliminary report.

J E Slater, G Raphael, G B Cutler, D L Loriaux, W J Meggs, M Kaliner.   

Abstract

Recurrent idiopathic anaphylaxis is an illness consisting of recurring anaphylactic or anaphylactoid attacks of unknown cause. A patient has been described whose attacks appeared to be associated with endogenous progesterone secretion and who was treated successfully with an analog of luteinizing hormone-releasing hormone (LHRH). This report summarizes the treatment of four additional women with recurrent anaphylaxis in a randomized, double-blind trial of an LHRH agonist and placebo. Two out of the four women experienced remission of their symptoms with the LHRH analog. The patients who responded to therapy had experienced systemic anaphylactoid reactions after provocation with an LHRH infusion and the intradermal injection of medroxyprogesterone; the nonresponders had no adverse reactions to either challenge. Ovarian suppression with LHRH agonist may benefit a subset of women with recurrent idiopathic anaphylaxis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3306508

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

Review 1.  Progestogen Hypersensitivity.

Authors:  Rung-Chi Li; Kathleen M Buchheit; Jonathan A Bernstein
Journal:  Curr Allergy Asthma Rep       Date:  2018-01-19       Impact factor: 4.806

Review 2.  Progestogen Sensitization: a Unique Female Presentation of Anaphylaxis.

Authors:  Jonathan A Bernstein
Journal:  Curr Allergy Asthma Rep       Date:  2020-01-28       Impact factor: 4.806

Review 3.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

4.  Autoimmune progesterone dermatitis in a patient with endometriosis: case report and review of the literature.

Authors:  Alan P Baptist; James L Baldwin
Journal:  Clin Mol Allergy       Date:  2004-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.